

May 10, 1972

Editor
Science
1515 Massachusetts Avenue, N.W.
Washington, D.C. 20005

Dear Sir:

We are pleased to submit the report "Naloxone Pamoate: A Long-Acting Opiate Antagonist" for your consideration.

As your columns have noted, narcotic antagonists represent a logical applied approach to both the treatment and the prevention of opiate dependence. While naloxone pamoate does not satisfy our clinical needs, the extension of duration of action with safety demonstrates the feasibility of such approaches.

Referees for this study may include:

Jonathan O. Cole, M.D.
Boston State Hospital
Boston, Massachusetts 02124

Jerome H. Jaffe, M.D.
SAODAP
White House
Washington, D.C.

William R. Martin, M.D.
NIMH Research Facility
Lexington, Kentucky

Editor

May 10, 1972

Irwin J. Pachter, M.D.
Bristol Laboratories
Syracuse, New York 13201

Robert H. Rees, M.D.
Sterling Winthrop Laboratories
90 Park Avenue
New York City 10016

Thank you for your consideration.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:ig
Enc.